COMPASS Pathways (“COMPASS Pathways” or the “Company”) (NASDAQ: CMPS) is a clinical stage mental healthcare company pioneering the development of psilocybin therapy, with an initial focus on TRD, a subset of MDD, comprising 100M patients who are inadequately served two or more antidepressant treatments.